CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
CCN2/CTGF
Cerebrospinal fluid (CSF)
Experimental autoimmune encephalomyelitis (EAE)
Multiple sclerosis
Primary progressive
Relapsing remitting
Remyelination
Secondary progressive
Serum
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 10 2022
15 10 2022
Historique:
received:
17
04
2022
revised:
19
07
2022
accepted:
24
07
2022
pubmed:
5
8
2022
medline:
15
9
2022
entrez:
4
8
2022
Statut:
ppublish
Résumé
Connective tissue growth factor (CTGF/CCN2) is a proinflammatory and an oligodendrocyte-differentiating blocking agent. It is found in MS lesions, which raises the possibility of involvement in MS pathogenesis. We found that its CSF and serum levels were higher in RR-MS patients than in controls and for serum compared to PP and SP-MS. Immune cells of both RR-MS and controls secreted CTGF/CCN2, which was enhanced by CD3/CD28 stimulation or by LPS. Anti-CTGF treatment of mice with experimental autoimmune encephalitis ameliorated its clinical severity. CTGF/CCN2 may play a role in the immune pathogenesis of MS and in remyelination failure in early stages of MS.
Identifiants
pubmed: 35926331
pii: S0165-5728(22)00131-X
doi: 10.1016/j.jneuroim.2022.577936
pii:
doi:
Substances chimiques
CCN2 protein, mouse
0
Connective Tissue Growth Factor
139568-91-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
577936Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.